RS52053B - Proces za pripremanje raspršivanjem osušenih formulacija tmc125 - Google Patents

Proces za pripremanje raspršivanjem osušenih formulacija tmc125

Info

Publication number
RS52053B
RS52053B RS20110527A RSP20110527A RS52053B RS 52053 B RS52053 B RS 52053B RS 20110527 A RS20110527 A RS 20110527A RS P20110527 A RSP20110527 A RS P20110527A RS 52053 B RS52053 B RS 52053B
Authority
RS
Serbia
Prior art keywords
tmc
compound
polymer
microcrystalline cellulose
tmc125
Prior art date
Application number
RS20110527A
Other languages
English (en)
Serbian (sr)
Inventor
Filip Rene Irene Kiekens
Jody Firmin Marceline Voorspoels
Lieven Elvire Colette Baert
Original Assignee
Tibotec Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37179187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52053(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals filed Critical Tibotec Pharmaceuticals
Publication of RS52053B publication Critical patent/RS52053B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20110527A 2006-06-06 2007-06-06 Proces za pripremanje raspršivanjem osušenih formulacija tmc125 RS52053B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06115029 2006-06-06

Publications (1)

Publication Number Publication Date
RS52053B true RS52053B (sr) 2012-04-30

Family

ID=37179187

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110527A RS52053B (sr) 2006-06-06 2007-06-06 Proces za pripremanje raspršivanjem osušenih formulacija tmc125

Country Status (26)

Country Link
US (2) US20090197903A1 (de)
EP (1) EP2029110B1 (de)
JP (1) JP5089685B2 (de)
KR (1) KR101179905B1 (de)
CN (1) CN101453989B (de)
AT (1) ATE522202T1 (de)
AU (1) AU2007255418C1 (de)
BR (1) BRPI0712346B8 (de)
CA (1) CA2651665C (de)
CY (1) CY1112154T1 (de)
DK (1) DK2029110T3 (de)
EC (1) ECSP088938A (de)
ES (1) ES2372983T3 (de)
HR (1) HRP20110883T1 (de)
IL (1) IL195710A (de)
ME (1) ME01305B (de)
MX (1) MX2008015686A (de)
NO (1) NO343652B1 (de)
NZ (1) NZ572702A (de)
PL (1) PL2029110T3 (de)
PT (1) PT2029110E (de)
RS (1) RS52053B (de)
RU (1) RU2406502C2 (de)
SI (1) SI2029110T1 (de)
WO (1) WO2007141308A1 (de)
ZA (1) ZA200810345B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2263671B1 (de) * 2008-04-02 2016-07-20 Astellas Pharma Inc. Amidderivathaltige pharmazeutische zusammensetzung
EP2306980A2 (de) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Rekonstitutionspulver
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
CN104684545B (zh) * 2012-09-27 2018-04-03 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
WO2019216700A1 (ko) * 2018-05-11 2019-11-14 주식회사 삼양사 고체 분산체, 이의 제조 방법, 이를 이용한 사슬 연장된 폴리우레탄 및 이를 포함하는 에폭시 수지 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2920956B2 (ja) * 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US6395303B1 (en) 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
TR200200763T2 (tr) * 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
BR0307515A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1575563B1 (de) * 2002-12-19 2007-02-14 Pharmacia Corporation Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält
ES2667668T3 (es) * 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv

Also Published As

Publication number Publication date
SI2029110T1 (sl) 2012-01-31
AU2007255418B2 (en) 2010-12-23
NO20090061L (no) 2009-01-06
CN101453989B (zh) 2012-06-13
HK1129579A1 (en) 2009-12-04
PL2029110T3 (pl) 2012-03-30
ATE522202T1 (de) 2011-09-15
AU2007255418A1 (en) 2007-12-13
BRPI0712346A2 (pt) 2012-07-17
RU2406502C2 (ru) 2010-12-20
CA2651665C (en) 2010-04-27
BRPI0712346B1 (pt) 2020-09-29
WO2007141308A1 (en) 2007-12-13
MX2008015686A (es) 2009-01-12
EP2029110B1 (de) 2011-08-31
RU2008152411A (ru) 2010-07-20
NO343652B1 (no) 2019-04-29
KR101179905B1 (ko) 2012-09-07
US20120208834A1 (en) 2012-08-16
CN101453989A (zh) 2009-06-10
DK2029110T3 (da) 2011-12-19
US20090197903A1 (en) 2009-08-06
JP5089685B2 (ja) 2012-12-05
IL195710A (en) 2014-02-27
ECSP088938A (es) 2009-01-30
ZA200810345B (en) 2012-05-30
ES2372983T3 (es) 2012-01-30
CY1112154T1 (el) 2015-12-09
CA2651665A1 (en) 2007-12-13
NZ572702A (en) 2011-09-30
HRP20110883T1 (hr) 2012-01-31
KR20090024131A (ko) 2009-03-06
US9603803B2 (en) 2017-03-28
EP2029110A1 (de) 2009-03-04
BRPI0712346B8 (pt) 2021-05-25
JP2009539804A (ja) 2009-11-19
ME01305B (me) 2012-04-30
IL195710A0 (en) 2009-09-01
PT2029110E (pt) 2011-11-23
AU2007255418C1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
US6872336B2 (en) Process for producing a pharmaceutical solid preparation containing a poorly soluble drug
KR20120101439A (ko) 프로페인-1-설폰산 ｛3-〔5-(4-클로로-페닐)-1ｈ-피롤로〔2,3-ｂ〕피리딘-3-카보닐〕-2,4-다이플루오로-페닐｝-아마이드 조성물 및 그의 용도
CN102458373A (zh) 生物利用度提高的包含难溶性药物的微球及其制备方法
US9603803B2 (en) Process for preparing spray dried formulations of 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile
EP2104491B1 (de) Hydrobromidsalz einer anti-hiv-verbindung
CN101790371A (zh) 包含达芦那韦和依曲韦林的组合制剂
WO2008076780A2 (en) Amorphous valsartan and the production thereof
JPWO2019107412A1 (ja) 固体分散体
Tran et al. Solubilization of poorly water-soluble drugs using solid dispersions
JP6141580B2 (ja) ラノラジンおよびドロネダロンの医薬組成物
AU2007300071A1 (en) Atorvastatin pharmaceutical compositions
WO2024095137A1 (en) Pharmaceutical composition of empagliflozin and process thereof
WO2002100407A1 (en) Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
HK1129579B (en) Process for preparing spray dried formulations of tmc125
US20250319029A1 (en) Composite comprising amorphous solid dispersion
EP2705839B1 (de) Pharmazeutische zusammensetzung mit lacidipin und herstellungsverfahren